ucb-34714 and Neuralgia

ucb-34714 has been researched along with Neuralgia* in 2 studies

Reviews

1 review(s) available for ucb-34714 and Neuralgia

Article	Year
Brivaracetam UCB. Current opinion in investigational drugs (London, England : 2000), 2005, Volume: 6, Issue:7 Brivaracetam (UCB-34714), an orally active, high-affinity synaptic vesicle protein 2A ligand, is being developed by UCB for the potential treatment of neurological disorders, namely epilepsy and neuropathic pain. By December 2003, UCB reported that phase II epilepsy trials had begun [517569]. Topics: Animals; Anticonvulsants; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Epilepsy; Humans; Molecular Structure; Neuralgia; Pyrrolidinones	2005

Article

Year

Current opinion in investigational drugs (London, England : 2000), 2005, Volume: 6, Issue:7

Brivaracetam (UCB-34714), an orally active, high-affinity synaptic vesicle protein 2A ligand, is being developed by UCB for the potential treatment of neurological disorders, namely epilepsy and neuropathic pain. By December 2003, UCB reported that phase II epilepsy trials had begun [517569].

Topics: Animals; Anticonvulsants; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Epilepsy; Humans; Molecular Structure; Neuralgia; Pyrrolidinones

2005

Other Studies

1 other study(ies) available for ucb-34714 and Neuralgia

Article	Year
[Brivaracetam - A Good Alternative in the Acute Treatment of Trigeminal Neuralgia]. Praxis, 2022, Volume: 110, Issue:1 Brivaracetam - A Good Alternative in the Acute Treatment of Trigeminal Neuralgia Topics: Humans; Neuralgia; Pyrrolidinones; Trigeminal Neuralgia	2022